Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers have hailed a ‘fantastic’ response from more than 1,700 GP practices who have stepped forward to contribute patient data for vital COVID-19 research from the Nuffield Department of Primary Care Health Sciences – tripling the amount of data available.

A blue keyboard and a doctor's stethoscope © Shutterstock

The data, which has already led to important published research on COVID-19 risk factors, has come from a daily pseudonymised feed from participating practices provided by EMIS since July.

EMIS has also given researchers at the University first access to its new powerful clinical data and analytics product. Built on the cloud-based EMIS-X platform, the new EMIS-X Analytics technology is now being piloted in a number of academic studies relating to COVID-19, ahead of its launch to NHS customers.

The response from GPs follows a joint appeal in March by the Oxford Royal College of General Practitioners Research and Surveillance Centre (Oxford RCGP RSC) at Oxford University's Nuffield Department of Primary Care Health Sciences, and clinical systems supplier EMIS, for practices to share their data under strict governance guidelines.

To date, 1,774 practices covering nearly 10 million patients have volunteered to take part in the COVID-19 research, significantly boosting the Oxford RCGP RSC’s network of practices from last year’s 500 practices.

Professor Simon de Lusignan, Director of the RSC, said he was ‘delighted’ by the response from GPs. “We had a resource before, but it is on a fantastic scale now, and is already helping us to answer important questions about COVID-19.

“The sheer numbers coming forward have surprised and delighted me, but primary care has really stepped up to the plate on all fronts in this crisis. It would be difficult to do this research without carefully coded primary care data. For example, ethnicity is well recorded by many GP practices, and this was vital to help us understand the impact of COVID-19 on BAME communities.”

The data is enabling the researchers to understand the spread of COVID-19, including tracking when it peaks and helping to inform strategy on local social distancing and lockdown. It is also being used to evaluate rapid COVID-19 finger prick tests against swab tests. Some practices are taking part in rapid clinical trials of antibiotics to reduce the duration and severity of the virus.

Dr Shaun O’Hanlon, Chief Medical Officer at EMIS, said: “We are proud that our advanced analytics technology is being deployed to support vital research at The University of Oxford. I’m very grateful to all the GPs who have come forward to share data and take part in the research, along with thousands of patients.

“The COVID-19 outbreak has highlighted the need to obtain good quality data quickly, and the power of data to make a difference. Our technology provides the secure, powerful processing tools needed by researchers, healthcare providers and government to answer important questions quickly by running complex queries over aggregated datasets at speed.”

Find out more about:

Sign-up for our newsletters

Contact our communications team

Our research media coverage

Our COVID-19 media coverage


Opinions expressed are those of the authors and not of Oxford University. Readers' comments will be moderated - see our guidelines for further information.

Similar stories

Thousands of patients may have undiagnosed and untreated bowel cancer due to COVID-19 disruption

COVID-19 Cancer Policy & health systems

A new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020.

Inhaled corticosteroids to be investigated as a possible treatment for Covid-19 in national PRINCIPLE Trial

COVID-19 Clinical trials Infection & acute care

In Covid-19, inhaled budesonide may prevent damaging inflammation, stop the virus from getting into lung cells and inhibit viral replication.

Two major pharmacy chains join PRINCIPLE Trial

COVID-19 Clinical trials

Two of the UK’s largest pharmacy chains, LloydsPharmacy and Well Pharmacy, are tasking their branches with helping to find suitable patients for the PRINCIPLE Trial of Covid-19 treatments.

Oxford to trial new COVID-19 test for individuals without symptoms

COVID-19 Infection & acute care

Led by a research team in the Nuffield Department of Primary Care Health Sciences, the University of Oxford will take part in a new pilot scheme to assess the use of Lateral Flow Tests (LFTs), a new COVID-19 test designed to identify asymptomatic individuals with the virus.

Study provides new estimates of breast cancer risks associated with HRT

Big data Cancer QResearch

Results add to existing knowledge and should help doctors and women make the best treatment choices

Britain’s most influential Hindu temple spreads awareness of the PRINCIPLE trial among Indian community

COVID-19 Clinical trials Infection & acute care

Europe’s BAPS Swaminarayan Sanstha, the largest Hindu temple outside of India, is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.